Multi-omics profiling identifies ADAM9 as a key efferocytosis driver in lung adenocarcinoma - Top-Institutions - MDSpire

Multi-omics profiling identifies ADAM9 as a key efferocytosis driver in lung adenocarcinoma

  • By

  • Guofu Lin

  • Lanlan Lin

  • Jianming Zhao

  • Gongping Chen

  • May 25, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, Texas

    Key Differentiators

    • Oncology

  • #2

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, New York

    Key Differentiators

    • Oncology

  • #3

    Washington University School of Medicine in St. Louis
    Washington University School of Medicine in St. Louis

    St. Louis, Missouri

    Key Differentiators

    • Oncology

  • #4

    The Cancer Genome Atlas
    The Cancer Genome Atlas

    N/A, N/A

    Key Differentiators

    • Genomics

  • #5

    Clinical Proteomic Tumor Analysis Consortium
    Clinical Proteomic Tumor Analysis Consortium

    N/A, N/A

    Key Differentiators

    • Proteomics

Original Source(s)

Multi-omics profiling identifies ADAM9 as a key efferocytosis driver in lung adenocarcinoma

  • by Guofu Lin, Lanlan Lin, Jianming Zhao, Gongping Chen

  • May 25, 2026

Related Content

Case Report: First description of an intracranial “NET” in ROHHAD syndrome; time to rename to the ROHHAD-NeCT syndrome?

The role of NAD+ metabolic reprogramming in colorectal cancer chemoresistance: mechanistic insights, clinical translation challenges and opportunities

Beyond inhibition: harnessing the DRD2–VEGF-A feedback loop for precision anti-angiogenesis therapy in cancer